index_ph001

Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana

pharmafile | October 14, 2019 | News story | Sales and Marketing  

Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with Lixiana (edoxaban).

Overall, results from Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation (ETNA-AF) at year one showed low rates of potentially life-threatening bleeding and low cardiovascular events in elderly NVAF patients treated with Lixiana.

The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical practice data on the use, effectiveness, and safety of a single NOAC in AF patients.

ISTH-defined major bleeding occurred in only 125 or 1.05% patients. Furthermore rates of systemic embolic events and myocardial infarction were generally low occurring in less than 0.5% of patients.

Raffaele de Caterina, Professor of Cardiology at the University of Pisa, said: “In routine clinical practice, the rates of major and clinically-relevant non-major (CRNM) bleeding in elderly edoxaban-treated patients were lower than those observed in clinical trial settings. Additionally, rates of all other cardiovascular events were also low in these patients.”

Wolfgang Zierhut, Executive Director of Medical Affair at Daiichi Sankyo Europe, added: “These positive results provide great insight into the safety and efficacy of edoxaban in NVAF patients, particularly in those who are elderly and/or those with comorbidities, who are considered at higher risk of cardiovascular events.”

Nik Kiran

Related Content

No items found

Latest content